drug · intermediate · complete
Retroviral gene therapy for SCID-X1
A gammaretroviral gene therapy that corrected X-linked severe combined immunodeficiency in most patients and caused T-cell leukaemia in several of them.
Also called: SCID-X1 gene therapy trial
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
What happened
Nine of ten infants with SCID-X1 had their immune systems restored by retroviral gene transfer into their own marrow cells. Years later, four of the nine developed T-cell leukaemia because the vector had inserted next to a cancer-promoting gene and its enhancer switched it on. Most were cured of the leukaemia by chemotherapy. 1
Reported, not yet replicated
The decisive reports more
In 2003 the investigators reported that almost 3 years after treatment, uncontrolled clonal proliferation of mature T cells had occurred in the two youngest patients; both clones had vector integration near the LMO2 proto-oncogene promoter, with aberrant LMO2 expression, most likely driven by retrovirus enhancer activity.
In 2008 they reported the two most recent cases: four of the nine successfully treated patients in all, 31 to 68 months after gene therapy; insertions near LMO2 and BMI1 in one and near CCND2 in another; chemotherapy gave sustained remission in 3 of 4 and restoration of polyclonal transduced T cells. 21
Reported, not yet replicated
Why it matters for expression control deep
This is the promoter-control question made lethal. An enhancer in the vector acts over distance, so a strong control element delivered to a random chromosome site can turn on a neighbour. This is why later vector designs focused on the enhancer; that claim is not shown in the sources opened here and is not carried as fact. 2
Our inference
Modality
Targets
Pathways
Indications
Identifiers
Vector
gammaretrovirus carrying IL2RG into autologous CD34+ bone-marrow cells
Mechanism
A gammaretroviral vector carried the IL2RG gene into the patient's own CD34+ bone-marrow cells outside the body; the corrected cells were returned. The vector integrates into the chromosome, so correction is copied when the cells divide, and the vector's own enhancer can act on nearby genes. 21
Reported, not yet replicated
Delivery route
Must survive
This is an ex vivo therapy: cells were treated in culture and given back, so the vector did not face the blood-borne immune system. The risk was in where it integrated. 1
Reported, not yet replicated
Side effects
T-cell leukaemia
4 of the 9 successfully treated patients developed T-cell leukaemia 31 to 68 months after gene therapy; chemotherapy led to sustained remission in 3 of the 4 and failed in the fourth. 1
Reported, not yet replicated
Verdict
Outcome
mixed
Why
The therapy corrected the immunodeficiency in 9 of 10 patients, and treated patients continued to benefit from the transferred gene, but 4 of the 9 developed leukaemia. Blast cells carried vector insertions near the proto-oncogenes LMO2, BMI1 and CCND2. The first two cases showed integration near the LMO2 promoter, most likely driven by retrovirus enhancer activity. 21
Reported, not yet replicated
Failure mode
Insertional oncogenesis: the integrated vector's enhancer activated a nearby growth-control gene in a developing T cell, which then acquired further genetic changes (translocations, NOTCH1 gain-of-function mutations and others) and became leukaemia, about 3 years after treatment in the first two cases. 21
Reported, not yet replicated
Teach this
In one sentence
A gene therapy that integrates into the chromosome lasts through cell division, but its built-in switch can wake a neighbouring cancer gene. 21
Reported, not yet replicated
The five-minute version
Infants with SCID-X1 lack a cytokine-receptor chain. Their own marrow stem cells were given a working copy using a retrovirus and returned. It worked for nine of ten. Years later four of those nine developed T-cell leukaemia; the blasts carried vector insertions beside LMO2, BMI1 or CCND2. The treatment was therapeutic and carcinogenic at once, and the mechanism was the vector's own enhancer. 21
Reported, not yet replicated
What a listener will ask
Did it work?
Yes for the immune deficiency in most patients, and treated patients continued to benefit after chemotherapy for the leukaemia.
The common wrong idea
Lasting gene therapy is safer than a transient one.
Integration gives durability through cell division, but it also lets the vector's control elements act on neighbouring genes for good.
The one citation to hand over: 1
Still open here
- The current regulatory status of this specific trial vector was not sourced; status here is "investigational" as a trial-stage therapy.
Not yet written: Assays used, Off targets.
Linked from
Sources
- Hacein-Bey-Abina S, Garrigue A, Wang GP, et al.. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. Journal of Clinical Investigation (2008). paper; opened 2026-11-17 all records citing this
- Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al.. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003). paper; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (5)
This record has been changed 5 times, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2003
- Regulatory status
- investigational
- Status
- complete
- Last updated
- 2026-11-19
- Record
- content/drugs/scid-x1-retroviral-gene-therapy.json